Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
Broadwood Partners and other investors are campaigning against STAAR Surgical’s proposed sale to Alcon at $28 per share in cash. They updated their LetSTAARShine.com website to include a CTFN article in which former STAAR CEO David Bailey argues the offer is far below earlier discussions reportedly “north of $50” per share plus a $7 performance kicker.
The article presents Bailey’s view that STAAR’s recent revenue drop reflects a temporary China disruption, not a lasting problem, and that the company’s EVO ICL lens and debt-free, cash-rich position justify a higher valuation. His and Pascal Aeschlimann’s modeling suggests standalone value of $28–$44 per share and a “right” takeover range of $50–$60, while STAAR’s board defends the $28 price as a 51% premium and stresses deal certainty.
The filing notes Broadwood and Yunqi Capital, holding 27.4% and 5.1% of STAAR shares, intend to vote against the transaction at the October 23 special meeting, framing the choice for stockholders as immediate cash versus remaining invested for potential future upside.
STAAR Surgical Company furnished an investor presentation and related press release explaining why its proposed merger with Alcon is presented as maximizing value for stockholders. These materials, dated September 26, 2025, are provided as exhibits and are described as being furnished under Regulation FD rather than filed, which limits their use in certain legal contexts. The company reminds investors that detailed information about the merger and the related vote is contained in its definitive proxy statement on Schedule 14A filed and first sent to stockholders on September 16, 2025. The communication also includes extensive forward-looking statement language outlining risks that could delay, prevent or affect the merger, such as failure to obtain stockholder or regulatory approvals, possible termination of the merger agreement, business disruption, retention of key personnel, potential legal proceedings, and stock price impacts if the transaction does not close.
STAAR Surgical proxy materials note that activist participant Broadwood launched a website, www.LetSTAARShine.com, and attached exhibits including a September 22, 2025 press release from investor Yunqi Capital and related research. The filing highlights product metrics: adoption in over 75 countries, more than 3 million implants over a 30-year period, and cost structure estimates of COGS ~29%, R&D ~9.5%, SG&A ~34%. It also cites projected market context (myopia affecting over 5 billion people by 2050) and per-share figures of $0.79 for 2025 or $1.46 if 2024 sales levels return.
STAAR Surgical Co. filed a PX14A6G disclosure containing excerpts from a 10-Q for the period ended June 27, 2025 filed on August 6, 2025. The 10-Q states that distributor inventory levels in China have decreased substantially since December 27, 2024 and returned to historical levels, and the company expects China revenue to normalize in the second half of fiscal 2025 as distributors rebuild purchases. The filing also reports a significant reduction in expenses and meaningful cost-efficiency potential, which the filer says supports a return to substantial profitability. The PX14A6G challenges the Board’s presentation of the Proposed Merger price of $28 per share, noting that while it equals ~59% and ~51% premiums to the 90-day VWAP and the closing price at announcement, it represents a ~26% discount to the 52-week high and a ~49% discount to Alcon’s prior $55 per share offer.
Yunqi Path Capital Master Fund and affiliated entities disclose ownership of 2,500,061 shares of STAAR SURGICAL CO, representing 5.1% of 49,354,123 shares outstanding. The shares were acquired beginning in 2023 using the fund's working capital and, other than ordinary-course working capital borrowings, no borrowed funds were used. The reporting persons state they will vote against the proposed merger with Alcon, issued an open letter explaining their view that the merger process and price are deficient, and note a special meeting of stockholders is scheduled for October 23, 2025.
Broadwood Partners and related investors have launched a proxy campaign to oppose the proposed acquisition of STAAR Surgical by Alcon. The group has filed a Schedule 13D/A and a preliminary proxy statement and plans to send a GREEN proxy card for the special meeting on October 23, 2025.
Broadwood Partners and Broadwood Capital may be deemed to beneficially own 13,519,491 STAAR shares each, and Neal C. Bradsher may be deemed to beneficially own 13,545,391 shares, together representing about 27.4% of the 49,354,123 shares outstanding as of September 12, 2025. They intend to solicit votes against both the merger agreement proposal and the advisory compensation proposal tied to the deal.
Broadwood group reports a 27.4% stake in STAAR Surgical (STAA) and is actively opposing the proposed merger with Alcon. The Reporting Persons—Broadwood Partners, Broadwood Capital and individuals including Neal C. Bradsher—may be deemed to beneficially own 13,519,491 shares out of 49,354,123 outstanding (approximately 27.4%). On September 15, 2025 they filed a preliminary proxy statement and a GREEN Proxy Card to solicit proxies to oppose approval of the Merger Agreement and a related non-binding compensation proposal at a special meeting scheduled for October 23, 2025. The Reporting Persons executed a Joint Filing and Solicitation Agreement on September 17, 2025 to coordinate filings and proxy solicitation; Broadwood Partners will bear pre-approved expenses. The filing discloses Mr. LeBuhn purchased 21,286 shares for approximately $135,888.02 from personal funds and that no Reporting Person transacted in the past 60 days.
STAAR Surgical Company (STAA) has entered into a merger agreement with Alcon under which STAAR stockholders will receive $28.00 per share in cash. The per-share price represented an approximately 51% premium to STAAR's closing price on August 4, 2025. Following the closing, STAAR common stock will no longer be listed and the company will cease to be publicly traded.
The board received a written fairness opinion from Citi dated August 4, 2025, and Citi used analyses that produced an implied per-share reference range of $17.70 to $37.50, adding STAAR net cash of $185 million and tax benefit present values in its valuation. The proxy discloses termination-fee mechanics, a go-shop/window period for superior proposals, employee award treatments (cash for in-the-money options; conversion or cancellation rules for RSUs/PSUs), and a Special Meeting to vote virtually on October 23, 2025. The proxy also includes multi-year financial projections showing revenue and adjusted EBITDA trajectories presented by STAAR to advisors.
Broadwood Partners, Broadwood Capital and Neal C. Bradsher disclose a combined stake in STAAR SURGICAL CO equal to 27.3% of the outstanding common stock. The filing states Broadwood Partners beneficially owns 13,519,491 shares and Mr. Bradsher beneficially owns 13,545,391 shares based on 49,553,035 shares outstanding. The Reporting Persons say they intend to vote against the definitive merger agreement under which Alcon would acquire STAAR and have issued a related press release. They also state they are exploring strategic alternatives, including contacting potential strategic and financial partners, and reserve the right to change their holdings or take other actions depending on market and deal developments.
STAAR Surgical Company (NASDAQ: STAA) has entered a merger agreement under which Alcon will acquire all outstanding STAAR shares for a Merger Consideration of $28.00 per share, representing an approximately 51% premium to STAAR's closing price on August 4, 2025. Upon closing STAAR will cease to be publicly listed and will be delisted. The parties intend to file required HSR notifications on or before September 2, 2025. Awards treatment: in‑the‑money options/payments will be cashed out; many RSU awards will be converted into Alcon RSUs using an RSU Exchange Ratio tied to Alcon's 5‑day VWAP before the Effective Time. Material termination provisions include potential STAAR termination fees (up to $43,425,000, reduced in certain circumstances to $14,475,000), an Alcon termination fee of $72,375,000, and specified regulatory closing conditions. STAAR disclosed management projections (2025E revenue ~$260M rising to ~$495M by 2030E) and noted non‑GAAP measures and tax gross‑up arrangements capped at an aggregate $15 million.